Subscribe
istock-519319356_charlieaja
charlieAJA / iStockphoto.com
19 July 2017Big Pharma

Pharma organisations underline Brexit concerns in letter to negotiators

The Association of the British Pharmaceutical Industry (ABPI) and seven other UK and European life sciences bodies have jointly written to the UK and EU Brexit negotiators.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
AstraZeneca seeks three-year Brexit transition period
5 October 2017   The chairman of pharmaceutical company AstraZeneca wants a transition period of three years following the UK’s exit from the EU.
Big Pharma
Brexit draft deal: a welcome step but more certainty needed, say lawyers
16 November 2018   While the pharmaceutical industry has welcomed the draft Withdrawal Agreement for the UK’s departure from the EU, more clarity is still needed, lawyers have told LSIPR.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Big Pharma
AstraZeneca seeks three-year Brexit transition period
5 October 2017   The chairman of pharmaceutical company AstraZeneca wants a transition period of three years following the UK’s exit from the EU.
Big Pharma
Brexit draft deal: a welcome step but more certainty needed, say lawyers
16 November 2018   While the pharmaceutical industry has welcomed the draft Withdrawal Agreement for the UK’s departure from the EU, more clarity is still needed, lawyers have told LSIPR.

More on this story

Big Pharma
AstraZeneca seeks three-year Brexit transition period
5 October 2017   The chairman of pharmaceutical company AstraZeneca wants a transition period of three years following the UK’s exit from the EU.
Big Pharma
Brexit draft deal: a welcome step but more certainty needed, say lawyers
16 November 2018   While the pharmaceutical industry has welcomed the draft Withdrawal Agreement for the UK’s departure from the EU, more clarity is still needed, lawyers have told LSIPR.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent